FDA mandates blindness risk warnings for GLP-1 medications

Nov 10, 10:52 PM2 min readCovered by 4 outlets

Drafted by AI from the sources below, published by the Ajako Taja Editorial Team · How we use AI

AI Summary

The FDA is requiring new labels for GLP-1 drugs like Ozempic after finding an increased risk of a rare condition that causes permanent vision loss.

The U.S. Food and Drug Administration has ordered manufacturers of GLP-1 drugs to add warning labels about a rare eye condition that can cause sudden and permanent blindness.

The federal mandate applies to all GLP-1 receptor agonists, including popular weight-loss and diabetes brands such as Ozempic, Wegovy, Mounjaro, and Zepbound. According to the FDA, these medications must now list information about nonarteritic anterior ischemic optic neuropathy, or NAION. This rare disorder involves a loss of blood flow to the optic nerve, resulting in a sudden, painless drop in vision for which there is currently no corrective treatment.

The Guardian and BBC News noted that NAION is the most frequent cause of sudden optic nerve damage in patients over 50. However, NBC News cited it as the second most common disease affecting the optic nerve in the United States. Following a review of 126 clinical trials, the FDA reported that for every 100,000 person-years of use, GLP-1 patients saw 6.4 cases of NAION, while those on placebos or other glucose treatments saw only 3.8 cases.

Medical experts emphasize that the overall danger to individuals remains low. The American Academy of Ophthalmology told the BBC that while patients should see a specialist if they notice vision changes, they should not stop taking their prescribed medication without medical advice. Dr. Manjot Gill, a Chicago-based ophthalmologist, told NBC News that while the FDA's decision is appropriate for public awareness, there is little reason for immediate anxiety because the condition is so infrequent.

Drugmakers Novo Nordisk and Eli Lilly stated that they prioritize the safety of their patients. A spokesperson for Novo Nordisk told the BBC that the current figures do not prove the medication causes the eye condition. The FDA acknowledged the difficulty in establishing a direct link, noting that the agency could not identify a biological mechanism and that patients using these drugs often have existing risk factors like hypertension and obesity.

Background

The FDA began its investigation following a 2024 JAMA Ophthalmology study that linked semaglutide use to higher NAION rates. GLP-1 medications already include warnings for other potential complications such as pancreatitis and gallbladder issues.